(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(0.11%) $83.66
(-3.32%) $1.920
(0.30%) $2 349.60
(-0.43%) $27.52
(0.42%) $924.40
(0.32%) $0.935
(0.67%) $11.02
(0.13%) $0.800
(-0.07%) $92.11
-0.49% $ 1.025
Live Chart Being Loaded With Signals
Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology and hematology drug products. The company's products under development include Eflapegrastim, a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia; Poziotinib, a novel irreversible tyrosine kinase inhibitor for non-small cell lung cancer tumors with various mutations; and Anti-CD20-IFNa, an antibody-interferon fusion molecule directed against CD20 that is in Phase I development for the treatment of patients with relapsed or refractory non-Hodgkin's lymphoma, including diffuse large B-cell lymphoma...
Stats | |
---|---|
Tagesvolumen | 4.85M |
Durchschnittsvolumen | 1.64M |
Marktkapitalisierung | 210.38M |
EPS | $0 ( 2024-03-20 ) |
Nächstes Ertragsdatum | ( $0 ) 2024-05-07 |
Last Dividend | $0.150 ( 2012-12-18 ) |
Next Dividend | $0 ( N/A ) |
P/E | -2.85 |
ATR14 | $0.0510 (4.95%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-07-31 | Bradrick Brittany | Sell | 27 380 | Common Stock, $0.001 par value |
2023-07-31 | Bradrick Brittany | Sell | 86 301 | Stock Option (Right to Buy) |
2023-07-31 | Mcgahan Keith M | Sell | 195 485 | Common Stock, $0.001 par value |
2023-07-31 | Mcgahan Keith M | Sell | 386 057 | Common Stock, $0.001 par value |
2023-07-31 | Mcgahan Keith M | Sell | 778 000 | Stock Option (Right to Buy) |
INSIDER POWER |
---|
-27.56 |
Last 97 transactions |
Buy: 24 888 642 | Sell: 15 180 768 |
Volumen Korrelation
Spectrum Pharmaceuticals Korrelation
10 Am meisten positiv korreliert | |
---|---|
IRMD | 0.941 |
IDCC | 0.939 |
SLMBP | 0.939 |
DRNA | 0.933 |
PRAA | 0.924 |
MESA | 0.923 |
PIRS | 0.923 |
GALT | 0.922 |
HLIO | 0.92 |
IOAC | 0.919 |
10 Am meisten negativ korreliert | |
---|---|
GMII | -0.923 |
AVIR | -0.911 |
TUEM | -0.907 |
JRJC | -0.896 |
AFYA | -0.896 |
EAR | -0.887 |
GSMG | -0.885 |
DTSS | -0.883 |
ATSG | -0.881 |
GOEV | -0.88 |
Wussten Sie das?
Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).
Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.
Spectrum Pharmaceuticals Korrelation - Währung/Rohstoff
Spectrum Pharmaceuticals Finanzdaten
Annual | 2022 |
Umsatz: | $10.11M |
Bruttogewinn: | $8.32M (82.28 %) |
EPS: | $-0.430 |
FY | 2022 |
Umsatz: | $10.11M |
Bruttogewinn: | $8.32M (82.28 %) |
EPS: | $-0.430 |
FY | 2021 |
Umsatz: | $0.00 |
Bruttogewinn: | $0.00 (0.00 %) |
EPS: | $-1.020 |
FY | 2020 |
Umsatz: | $0.00 |
Bruttogewinn: | $0.00 (0.00 %) |
EPS: | $-1.290 |
Financial Reports:
No articles found.
Spectrum Pharmaceuticals Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
First Dividend | $0.150 | 2012-12-18 |
Last Dividend | $0.150 | 2012-12-18 |
Next Dividend | $0 | N/A |
Payout Date | 2012-12-28 | |
Next Payout Date | N/A | |
# dividends | 1 | -- |
Total Paid Out | $0.150 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 0.01 | -- |
Div. Sustainability Score | 0 | |
Div.Growth Potential Score | 0 | |
Div. Directional Score | 0 | -- |
Year | Amount | Yield |
---|---|---|
2012 | $0.150 | 1.02% |
2013 | $0 | 0.00% |
2014 | $0 | 0.00% |
2015 | $0 | 0.00% |
2016 | $0 | 0.00% |
2017 | $0 | 0.00% |
2018 | $0 | 0.00% |
2019 | $0 | 0.00% |
2020 | $0 | 0.00% |
2021 | $0 | 0.00% |
2022 | $0 | 0.00% |
2023 | $0 | 0.00% |
2024 | $0 | 0.00% |
The company does not currently pay dividends. Given its current dividend status and a low Dividend Growth Potential Score (DGPS), there's minimal likelihood of dividends being initiated soon. Considering all factors, the near-term dividend outlook for the company remains unpromising.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
PSEC | Dividend Royal | 2023-12-26 | Monthly | 21 | 7.04% | 8.50 |
SLVO | Dividend Royal | 2023-11-20 | Monthly | 12 | 10.77% | 8.50 |
QYLD | Dividend Royal | 2023-11-20 | Monthly | 11 | 7.50% | 8.50 |
GAIN | Dividend Royal | 2023-12-04 | Monthly | 20 | 8.19% | 8.50 |
GLDI | Dividend Royal | 2023-11-20 | Monthly | 12 | 7.15% | 8.50 |
OXLC | Dividend Royal | 2023-12-14 | Monthly | 14 | 10.00% | 8.50 |
OXSQ | Dividend Diamond | 2023-12-14 | Monthly | 21 | 9.10% | 8.50 |
HRZN | Dividend King | 2023-12-18 | Monthly | 15 | 6.60% | 8.45 |
USOI | Dividend Royal | 2023-11-20 | Monthly | 8 | 16.70% | 8.28 |
PFLT | Dividend King | 2023-11-15 | Monthly | 14 | 6.50% | 8.27 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -1.400 | 1.500 | -10.00 | -10.00 | [0 - 0.5] |
returnOnAssetsTTM | -0.334 | 1.200 | -10.00 | -10.00 | [0 - 0.3] |
returnOnEquityTTM | -1.193 | 1.500 | -10.00 | -10.00 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 2.71 | 0.800 | 1.449 | 1.159 | [1 - 3] |
quickRatioTTM | 2.31 | 0.800 | 1.124 | 0.899 | [0.8 - 2.5] |
cashRatioTTM | 1.347 | 1.500 | 3.63 | 5.44 | [0.2 - 2] |
debtRatioTTM | 0.275 | -1.500 | 5.42 | -8.12 | [0 - 0.6] |
interestCoverageTTM | -19.33 | 1.000 | -8.27 | -8.27 | [3 - 30] |
operatingCashFlowPerShareTTM | -0.320 | 2.00 | -0.107 | -0.214 | [0 - 30] |
freeCashFlowPerShareTTM | -0.322 | 2.00 | -0.161 | -0.322 | [0 - 20] |
debtEquityRatioTTM | 1.105 | -1.500 | 5.58 | -8.37 | [0 - 2.5] |
grossProfitMarginTTM | 0.889 | 1.000 | 10.00 | 10.00 | [0.2 - 0.8] |
operatingProfitMarginTTM | -1.481 | 1.000 | -10.00 | -10.00 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | -2.18 | 1.000 | -10.00 | -10.00 | [0.2 - 2] |
assetTurnoverTTM | 0.239 | 0.800 | -1.740 | -1.392 | [0.5 - 2] |
Total Score | -3.02 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -5.75 | 1.000 | -0.682 | 0 | [1 - 100] |
returnOnEquityTTM | -1.193 | 2.50 | -9.24 | -10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -0.322 | 2.00 | -0.107 | -0.322 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -0.320 | 2.00 | -0.107 | -0.214 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 0.583 | 1.500 | 9.45 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | -2.51 | 1.000 | -10.00 | 0 | [0.1 - 0.5] |
Total Score | -1.111 |
Spectrum Pharmaceuticals
Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology and hematology drug products. The company's products under development include Eflapegrastim, a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia; Poziotinib, a novel irreversible tyrosine kinase inhibitor for non-small cell lung cancer tumors with various mutations; and Anti-CD20-IFNa, an antibody-interferon fusion molecule directed against CD20 that is in Phase I development for the treatment of patients with relapsed or refractory non-Hodgkin's lymphoma, including diffuse large B-cell lymphoma. It has co-development, commercialization, and in-license agreements with Hanmi Pharmaceutical Co. Ltd.; a patent and technology license agreement with The University of Texas M.D. Anderson Cancer Center; and in-license agreement with ImmunGene, Inc. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was incorporated in 1987 and is based in Boston, Massachusetts.
Über Live-Signale
Die Live-Signale auf dieser Seite helfen dabei zu bestimmen, wann man NA kaufen oder verkaufen soll. Die Signale haben eine Verzögerung von bis zu 1 Minute; wie bei allen Marktsignalen besteht die Möglichkeit von Fehlern oder Fehleinschätzungen.
Die Live-Handelssignale sind nicht endgültig und getagraph.com übernimmt keine Verantwortung für Maßnahmen, die aufgrund dieser Signale ergriffen werden, wie in den Nutzungsbedingungen beschrieben. Die Signale basieren auf einer breiten Palette von technischen Analyseindikatoren.